Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NDAQ vs CME: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NDAQ Captures Overall Composite Edge (45.2 HOLD vs 38.6 SELL), While CME Leads 4–2 on Growth & Valuation Pillars

NDAQ Overall Winner 6-Pillar Tally: NDAQ 2 – 4 CME Matrix Metrics: NDAQ 3 – 7 CME

As of Nov 17, 2026, Nasdaq, Inc. (NDAQ) captures the overall head-to-head institutional edge over CME Group Inc. (CME) on higher Unified Composite conviction (45.2/100 HOLD vs. 38.6/100 SELL) after splitting the core matrix 3–7 (led by Valuation Multiples, R&D & Supply-Chain Moat), while CME wins 4–2 across the 6-pillar growth and valuation breakdown. NDAQ trades at $105.32 (22.9x Forward P/E, 49.0% operating margin) versus CME at $311.77 (24.1x Forward P/E, 66.2% operating margin).

  • Growth vs. Quality Trade-Off: NDAQ earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. CME 38.6/100 SELL) and 0.43β · 32% Vol risk profile, whereas CME leads top-line expansion (+13.0% YoY revenue growth, 4.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NDAQ vs CME
NDAQ NASDAQ Head-to-Head Winner
Nasdaq, Inc. Common Stock
Security & Commodity Brokers, Dealers, Exchanges & Services
$105.32
-2.95% 1D
Market Cap $60.2B
TTM Revenue $5.78B
Forward P/E 22.9x
Beta / 30D Vol 0.43β · 32% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.8% over 20 days), RSI 57
RSI-14: 57.3 · SMA20: $106.40 · SMA50: $98.17
CME NASDAQ
CME Group Inc.
Security & Commodity Brokers, Dealers, Exchanges & Services
$311.77
-2.38% 1D
Market Cap $113.8B
TTM Revenue $6.96B
Forward P/E 24.1x
Beta / 30D Vol -0.32β · 26% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 19.0 Fund 29.0 Flow 55.0 Mom 11.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 63
RSI-14: 63.1 · SMA20: $306.50 · SMA50: $287.47

6-Pillar Scorecard Institutional Category Breakdown (NDAQ 2 – 4 CME)

Columns: Metric · NDAQ · CME
1. Valuation Multiples NDAQ
Forward P/E 22.9x 24.1x
Trailing P/E 29.6x 26.1x
PEG Ratio 1.68x 4.38x
EV / Revenue 11.9x 16.5x
2. Growth & Scale CME
Revenue Growth (YoY) +12.6% +13.0%
Earnings Growth (YoY) +31.5% +16.1%
TTM Revenue (USD) $5.78B $6.96B
Market Cap $60.2B $113.8B
3. Profitability & Quality CME
Gross Margin 100.0% 100.0%
Operating Margin 49.0% 66.2%
Net Profit Margin 36.1% 63.5%
Return on Equity (ROE) 17.3% 16.1%
4. Balance Sheet & Cash Flow CME
Cash Generation (TTM) $2.26B $4.33B
Cash Flow Margin 39.1% 62.3%
Net Cash / Leverage $8.85B Net Debt (0.77x D/E) $1.23B Net Debt (0.13x D/E)
Dividend Yield 1.07% 1.63%
5. Options & Positioning CME
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 35.8% (10th %ile) 24.0% (10th %ile)
Put/Call OI Skew 0.57x (Call-Skewed) 0.40x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat NDAQ
OpEx & R&D Intensity 51.0% of Rev ($2.95B) 33.8% of Rev ($2.35B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Financial Data & Stock Exchanges Operator Financial Data & Stock Exchanges Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NDAQ (3) vs CME (7)
Institutional Metric NDAQ CME Criterion Row Edge
Market Capitalization
Scale
$60.2B $113.8B Larger Scale CME
Trailing P/E Ratio
Valuation
29.6x 26.1x Lower Multiple CME
Forward P/E Ratio
Valuation
22.9x 24.1x Lower Multiple NDAQ
Revenue Growth (YoY)
Growth
+12.6% +13.0% Higher Growth CME
Operating Margin (TTM)
Profitability
49.0% 66.2% Higher Margin CME
Net Profit Margin
Profitability
36.1% 63.5% Higher Margin CME
Return on Equity (ROE)
Capital Efficiency
17.3% 16.1% Higher ROE NDAQ
52-Week Range Position
Momentum
82% ($77–$111) 84% ($218–$329) Stronger Trend CME
Beta / 30D Volatility
Risk Regime
0.43β · 32% Vol -0.32β · 26% Vol Lower Realized Risk CME
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 38.6 / 100 (SELL) Higher Composite NDAQ
Trailing 12M Revenue (USD)
Operating Scale
$5.78B $6.96B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.68x PEG · 11.9x EV/Rev 4.38x PEG · 16.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.26B ($8.85B Net Debt (0.77x D/E)) $4.33B ($1.23B Net Debt (0.13x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NDAQ +6.79 pp
NDAQ: +13.0% · CME: +6.21%
3M Horizon CME +7.48 pp
NDAQ: +9.31% · CME: +16.79%
6M Horizon NDAQ +11.39 pp
NDAQ: +14.5% · CME: +3.11%
1Y Horizon NDAQ +11.57 pp
NDAQ: +20.95% · CME: +9.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NDAQ Revenue CME Revenue NDAQ Op. Margin CME Op. Margin Margin Leader
FY2018 $4.28B $4.31B 24.0% 60.5% CME
FY2019 $4.26B $4.87B 23.9% 53.2% CME
FY2020 $5.62B $4.88B 21.9% 54.0% CME
FY2021 $5.89B $4.69B 24.5% 56.4% CME
FY2022 $6.23B $5.02B 25.1% 60.1% CME
FY2023 $6.06B $5.58B 26.0% 61.6% CME
FY2024 $7.40B $6.13B 24.3% 64.1% CME
FY2025 $8.26B $6.52B 28.2% 64.9% CME

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NDAQ CONSOLIDATION
58d in phase · OBV DISTRIBUTION
Current IV 35.8%
IV Percentile 10th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact NDAQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CME CONSOLIDATION
54d in phase · OBV ACCUMULATION
Current IV 24.0%
IV Percentile 10th %ile
Put/Call OI Skew 0.40x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $108.52 · IV 25.6%

NDAQ vs. CME: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of NDAQ ($10,852) vs. CME ($31,937) against risk-defined 5-day vertical and put-wall option structures.

NDAQ Spot $108.52 · IV 25.6%
NDAQ Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $110 / $115 Bull Call Spread

Buy 1x $110C · Sell 1x $115C · 31d

Net Entry $63 Debit
T+5d @ +5% Move +$133 (+211%)
Max Risk / Buffer $63 Capped
5d Edge & Liquidity 2.2x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $100 / $92.5 Bull Put Spread

Sell 1x $100P · Buy 1x $92.5P · 59d

Net Entry $94 Credit
Max Credit / Yield +$94 (+14.3% RoM)
Max Risk / Buffer -8.7% Cushion ($656 Mgn)
5d Edge & Liquidity 81% PoP · Liq C
Simulate 5-Day Payoff →
CME Spot $319.37 · IV 24.8%
CME Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $320 / $330 Bull Call Spread

Buy 1x $320C · Sell 1x $330C · 31d

Net Entry $404 Debit
T+5d @ +5% Move +$307 (+76%)
Max Risk / Buffer $404 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $300 / $270 Bull Put Spread

Sell 1x $300P · Buy 1x $270P · 31d

Net Entry $304 Credit
Max Credit / Yield +$304 (+11.3% RoM)
Max Risk / Buffer -7.0% Cushion ($2,696 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NDAQ Moat Profile High-Margin Pricing Power Moat
Financial Data & Stock Exchanges Operator
Competes within the Financial Data & Stock Exchanges value chain with $60.2B market capitalization and 49.0% operating margin.
OpEx & R&D Reinvestment 51.0% of Rev ($2.95B)
90D Engineering Disclosures 0 Published
CME Moat Profile High-Margin Pricing Power Moat
Financial Data & Stock Exchanges Operator
Competes within the Financial Data & Stock Exchanges value chain with $113.8B market capitalization and 66.2% operating margin.
OpEx & R&D Reinvestment 33.8% of Rev ($2.35B)
90D Engineering Disclosures 0 Published

Investor FAQ NDAQ vs CME Key Questions & Quantitative Answers

As of Nov 17, 2026, Nasdaq, Inc. (NDAQ) captures the overall head-to-head institutional edge over CME Group Inc. (CME) on higher Unified Composite conviction (45.2/100 HOLD vs. 38.6/100 SELL) after splitting the core matrix 3–7 (led by Valuation Multiples, R&D & Supply-Chain Moat), while CME wins 4–2 across the 6-pillar growth and valuation breakdown. NDAQ trades at $105.32 (22.9x Forward P/E, 49.0% operating margin) versus CME at $311.77 (24.1x Forward P/E, 66.2% operating margin). Growth vs. Quality Trade-Off: NDAQ earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. CME 38.6/100 SELL) and 0.43β · 32% Vol risk profile, whereas CME leads top-line expansion (+13.0% YoY revenue growth, 4.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

CME leads the Growth & Scale pillar: NDAQ posts +12.6% YoY revenue growth and +31.5% YoY earnings growth on $5.78B TTM revenue (100.0% gross margin, 49.0% operating margin), compared with CME at +13.0% YoY revenue growth and +16.1% YoY earnings growth on $6.96B TTM revenue (100.0% gross margin, 66.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDAQ cumulative revenue shifted +93.0% while CME shifted +51.3%. In operating R&D and SG&A reinvestment, NDAQ deploys 51.0% of Rev ($2.95B) (0 90-day corporate R&D disclosures) versus 33.8% of Rev ($2.35B) (0 disclosures) for CME.

NDAQ screens cheaper on headline valuation multiples. NDAQ trades at 22.9x Forward P/E, 29.6x Trailing P/E, 1.68x PEG, and 11.9x EV/Revenue (39.1% FCF margin), whereas CME trades at 24.1x Forward P/E, 26.1x Trailing P/E, 4.38x PEG, and 16.5x EV/Revenue (62.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDAQ (17.3% ROE) versus CME (16.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NDAQ carries 35.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.43β · 32% Vol realized risk). By comparison, CME carries 24.0% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.32β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.